Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 127Neoplasm Metastasis 14Neoplasms 9Advanced Breast Cancer 6Endometrial Neoplasms 5Recurrence 4Hereditary Sensory and Autonomic Neuropathies 4Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Ovarian Neoplasms 3Neoplasms, Hormone-Dependent 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Lobular 3Carcinoma, Ductal, Breast 3Squamous Cell Carcinoma of Head and Neck 2Polycystic Ovary Syndrome 2Osteoporosis 2Neoplasms by Site 2Lymphoma, Non-Hodgkin 2Head and Neck Neoplasms 2HR+/HER2- Breast Cancer 2Breast Neoplasms, Male 2Breast Diseases 2Bone Diseases, Metabolic 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Small Cell Lung Carcinoma 1Osteitis Deformans 1Multiple Endocrine Neoplasia Type 1 1Mesothelioma, Malignant 1

Interventions

Carboplatin 71Etoposide 63Topotecan 42Cisplatin 38pembrolizumab 30atezolizumab 26durvalumab 22Paclitaxel 16Nivolumab 14PM 01183 13rovalpituzumab tesirine 11Pemetrexed 11amrubicin 9Ipilimumab 9Injections 9Irinotecan 8AMG 757 8trilaciclib 7etoposide phosphate 6EC regimen 6Drug Therapy 6Docetaxel 6Bevacizumab 6tremelimumab 5MLN 8237 5Gemcitabine 5130-nm albumin-bound paclitaxel 5olaparib 4chiauranib 4budigalimab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Small Cell Lung Carcinoma × Letrozole × Clear all
NCT04553133 2026-05-06

PF-07104091 as a Single Agent and in Combination Therapy

Pfizer

Phase 2 Active not recruiting
157 enrolled
BreastGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡